1
|
Milivojac T, Grabež M, Krivokuća A, Maličević U, Gajić Bojić M, Đukanović Đ, Uletilović S, Mandić-Kovačević N, Cvjetković T, Barudžija M, Vojinović N, Šmitran A, Amidžić L, Stojiljković MP, Čolić M, Mikov M, Škrbić R. Ursodeoxycholic and chenodeoxycholic bile acids attenuate systemic and liver inflammation induced by lipopolysaccharide in rats. Mol Cell Biochem 2024:10.1007/s11010-024-04994-2. [PMID: 38578526 DOI: 10.1007/s11010-024-04994-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 03/17/2024] [Indexed: 04/06/2024]
Abstract
Bacterial lipopolysaccharide (LPS) induces general inflammation, by activating pathways involving cytokine production, blood coagulation, complement system activation, and acute phase protein release. The key cellular players are leukocytes and endothelial cells, that lead to tissue injury and organ failure. The aim of this study was to explore the anti-inflammatory, antioxidant, and cytoprotective properties of two bile acids, ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) in LPS-induced endotoxemia in rats. The experiment involved six distinct groups of Wistar rats, each subjected to different pretreatment conditions: control and LPS groups were pretreated with propylene glycol, as a bile acid solvent, while the other groups were pretreated with UDCA or CDCA for 10 days followed by an LPS injection on day 10. The results showed that both UDCA and CDCA reduced the production of pro-inflammatory cytokines: TNF-α, GM-CSF, IL-2, IFNγ, IL-6, and IL-1β and expression of nuclear factor-κB (NF-κB) induced by LPS. In addition, pretreatment with these bile acids showed a positive impact on lipid profiles, a decrease in ICAM levels, an increase in antioxidant activity (SOD, |CAT, GSH), and a decrease in prooxidant markers (H2O2 and O2-). Furthermore, both bile acids alleviated LPS-induced liver injury. While UDCA and CDCA pretreatment attenuated homocysteine levels in LPS-treated rats, only UDCA pretreatment showed reductions in other serum biochemical markers, including creatine kinase, lactate dehydrogenase, and high-sensitivity troponin I. It can be concluded that both, UDCA and CDCA, although exerted slightly different effects, can prevent the inflammatory responses induced by LPS, improve oxidative stress status, and attenuate LPS-induced liver injury.
Collapse
Affiliation(s)
- T Milivojac
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - M Grabež
- Department of Hygiene, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - A Krivokuća
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Pathophysiology, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - U Maličević
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Pathophysiology, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - M Gajić Bojić
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - Đ Đukanović
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Pharmacy, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - S Uletilović
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Medical Biochemistry and Chemistry, Faculty of Medicine, The Republic of Srpska, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
| | - N Mandić-Kovačević
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Pharmacy, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - T Cvjetković
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Medical Biochemistry and Chemistry, Faculty of Medicine, The Republic of Srpska, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
| | - M Barudžija
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Histology and Embryology, Faculty of Medicine, The Republic of Srpska, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
| | - N Vojinović
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - A Šmitran
- Department of Microbiology and Immunology, Faculty of Medicine, The Republic of Srpska, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
| | - Lj Amidžić
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - M P Stojiljković
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
| | - M Čolić
- Medical Faculty Foča, University of East Sarajevo, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- Serbian Academy of Sciences and Arts, Belgrade, Serbia
| | - M Mikov
- Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
| | - R Škrbić
- Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina.
- Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, The Republic of Srpska, Banja Luka, Bosnia and Herzegovina.
| |
Collapse
|
2
|
Tiwari D, Aw TC. Optimizing the Clinical Use of High-Sensitivity Troponin Assays: A Review. Diagnostics (Basel) 2023; 14:87. [PMID: 38201396 PMCID: PMC10795745 DOI: 10.3390/diagnostics14010087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 12/14/2023] [Accepted: 12/29/2023] [Indexed: 01/12/2024] Open
Abstract
Ischemic heart diseases (IHDs) remain a global health concern. Many IHD cases go undiagnosed due to challenges in the initial diagnostic process, particularly in cases of acute myocardial infarction (AMI). High-sensitivity cardiac troponin (hs-cTn) assays have revolutionized myocardial injury assessment, but variations in diagnostic cut-off values and population differences have raised challenges. This review addresses essential laboratory and clinical considerations for hs-cTn assays. Laboratory guidelines discuss the importance of establishing standardized 99th-percentile upper reference limits (URLs) considering factors such as age, sex, health status, and analytical precision. The reference population should exclude individuals with comorbidities like diabetes and renal disease, and rigorous selection is crucial. Some clinical guidelines emphasize the significance of sex-specific URL limits while others do not. They highlight the use of serial troponin assays for AMI diagnosis. In addition, timely reporting of accurate hs-cTn results is essential for effective clinical use. This review aims to provide a clearer understanding among laboratory professionals and clinicians on how to optimize the use of hs-cTn assays in clinical settings in order to ensure accurate AMI diagnosis and thus improve patient care and outcomes.
Collapse
Affiliation(s)
- Dipti Tiwari
- Independent Researcher, Singapore 069046, Singapore;
| | - Tar Choon Aw
- Department of Laboratory Medicine, Changi General Hospital, Singapore 529889, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore 119228, Singapore
- Pathology Academic Clinical Program, Duke-NUS Graduate School of Medicine, Singapore 169857, Singapore
| |
Collapse
|